Polyneuropathy Following Vincristine Therapy in Two Patients With Charcot-Marie-Tooth Syndrome

Publisher Website
Google Scholar
Abstract
The neurotoxicity of vincristine sulfate, a commonly used antineoplastic agent, has been well described. A literature review failed to reveal any absolute contraindications to the initial use of vincristine. We describe two patients with nodular sclerosing Hodgkin's disease in whom a rapidly progressive, but reversible, severe polyneuropathy developed when they were given a total of 4 mg of vincristine sulfate. Each was later shown to have the demyelinating form of Charcot-Marie-Tooth syndrome. This association suggests that the use of vincristine is contraindicated in patients with the demyelinating form of Charcot-Marie-Tooth syndrome. (JAMA 1984;252:2862-2863)

This publication has 0 references indexed in Scilit: